Astellas Pharma v. Zydus Cadila: Xtandi Patent Case Consolidated in 98 Days
Astellas Pharma filed a patent infringement action against generic manufacturer Zydus Cadila in the District of New Jersey, asserting US11839689B2 covering its blockbuster Xtandi® enzalutamide tablets. Within 98 days, the case was consolidated with a parallel action — Civil Action No. 3:24-cv-09403 — centralising all proceedings before a single docket.
Astellas consolidates parallel Xtandi® ANDA actions in New Jersey
On October 11, 2024, Astellas Pharma, Inc. filed a patent infringement complaint against Zydus Cadila in the United States District Court for the District of New Jersey, asserting US11839689B2 in connection with Zydus’s ANDA filing targeting Xtandi® (enzalutamide) tablets in 40 mg and 80 mg strengths. Xtandi® is a leading androgen receptor inhibitor approved for the treatment of prostate cancer and represents a commercially significant asset in Astellas’s portfolio.
The case closed on January 17, 2025, when Astellas, Zydus Cadila, and co-defendant Haimen Pharma stipulated to consolidation with the related Civil Action No. 3:24-cv-09403. The consolidation order, subject to court approval, directed all future filings into the lead docket and deemed all pro hac vice admissions transferred. This mechanism is consistent with courts managing multiple ANDA challengers asserting the same patent against the same branded product.
The 98-day timeline to consolidation suggests the parties moved efficiently to rationalise parallel proceedings, likely reflecting coordinated ANDA filing schedules by multiple generic applicants. The public record does not disclose whether claim construction, invalidity contentions, or any substantive merits dispute had advanced before consolidation. The substantive outcome — including any potential 30-month stay expiry, settlement, or trial — remains to be determined in the lead consolidated action.
Filing to Case Consolidated in 98 days
98 days to consolidation — significantly faster than average ANDA patent litigation timelines
Case consolidated: what the merger of actions means for both parties
Consolidation joins parallel ANDA actions into one proceeding
Federal Rule of Civil Procedure 42(a) permits a court to consolidate actions sharing common questions of law or fact. Here, Astellas had filed separate infringement suits against at least two generic filers — Zydus Cadila and Haimen Pharma — asserting the same patent over the same product. Consolidation avoids duplicative discovery, inconsistent rulings, and wasted judicial resources, directing all activity into Civil Action No. 3:24-cv-09403.
FRCP 42(a) consolidationAstellas retains all claims; litigation continues in lead docket
Consolidation does not resolve the underlying infringement dispute. Astellas’s assertion of US11839689B2 against Zydus Cadila survives intact and will be litigated in the lead action. For Astellas, consolidation is typically advantageous: it allows coordinated claim construction positions and prevents inconsistent invalidity rulings across separate courts or dockets.
Claims preserved in lead actionZydus faces consolidated proceedings alongside Haimen Pharma
Zydus Cadila’s defences — likely including non-infringement and invalidity contentions typical of ANDA litigation — will now be coordinated with those of Haimen Pharma in the lead docket. This may streamline Zydus’s discovery burden but also means its litigation strategy will be more visible to a co-defendant. Zydus’s path to market for its generic enzalutamide product remains contingent on the outcome in the consolidated action.
Merits unresolved; path to market openXtandi® exclusivity window depends on consolidated trial outcome
Xtandi® (enzalutamide) is a multi-billion-dollar prostate cancer therapy. The consolidated ANDA litigation will determine whether generic entry is blocked by US11839689B2 or cleared by invalidity or non-infringement findings. Pharmaceutical sector stakeholders — including oncology payers and competing generic applicants — should monitor the lead docket (3:24-cv-09403) for claim construction orders and trial scheduling as key signals of generic entry timing.
Generic entry timing unresolvedFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Astellas Pharma, Inc. | Company | Japanese pharmaceutical company — holder of US11839689B2 covering Xtandi® enzalutamideSearch in Eureka ↗ |
| Defendant | Zydus Cadila | Individual | Indian generic pharmaceutical manufacturer; ANDA filer targeting Xtandi® tabletsSearch in Eureka ↗ |
| Plaintiff counsel | Christine Clark | Attorney | Counsel for Astellas Pharma, Inc.Search in Eureka ↗ |
| Plaintiff counsel | ERIN AUSTIN | Attorney | Counsel for Astellas Pharma, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Katelyn O’Reilly | Attorney | Counsel for Astellas Pharma, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Liza M. Walsh | Attorney | Counsel for Astellas Pharma, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Venable, LLP | Law Firm | Representing Astellas Pharma, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Walsh Pizzi O’reilly Falanga, LLP | Law Firm | Representing Astellas Pharma, Inc.Search in Eureka ↗ |
| Defendant counsel | Theodora T. Mccormick. | Attorney | Counsel for Zydus CadilaSearch in Eureka ↗ |
| Defendant law firm | Epstein Becker & Green, PC | Law Firm | Representing Zydus CadilaSearch in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | New Jersey District CourtSearch in Eureka ↗ |
Official order — verbatim text
The stipulation language reflects a procedural consolidation rather than any merits adjudication. The parties agreed to merge this action with Civil Action No. 3:24-cv-09403 ‘for all purposes, including discovery, case management, and trial.’ This phrasing confirms that no claims have been resolved, withdrawn, or adjudicated — the infringement dispute over US11839689B2 and Xtandi® tablets continues in full in the lead docket, with all previously admitted counsel carried over by operation of the consolidation order.
US11839689B2 — Xtandi® enzalutamide tablet formulation
US11839689B2, filed under application number 17/985,235, covers formulations related to Xtandi® (enzalutamide) tablets in 40 mg and 80 mg strengths. Enzalutamide is an androgen receptor signalling inhibitor approved for metastatic and non-metastatic castration-resistant and castration-sensitive prostate cancer. The patent’s issuance and assertion in ANDA litigation suggests it represents a later-generation formulation or method patent designed to extend commercially relevant exclusivity for the Xtandi® franchise.
For generic manufacturers, US11839689B2 represents a potential obstacle to market entry for enzalutamide tablets. The simultaneous filing of ANDA actions by at least two defendants — Zydus Cadila and Haimen Pharma — indicates that multiple generic applicants assessed the patent as susceptible to invalidity or non-infringement challenge. Companies developing or commercialising androgen receptor inhibitors or oncology tablet formulations in the prostate cancer space should assess their exposure to this patent and monitor the consolidated proceedings closely.
Should your enzalutamide product run an FTO against US11839689B2?
Any company developing generic or branded enzalutamide tablets, or related androgen receptor inhibitor formulations for prostate cancer, should treat US11839689B2 as a live freedom-to-operate concern. The patent is actively asserted in consolidated ANDA litigation in the District of New Jersey, and no invalidity or non-infringement finding has yet been issued. R&D and regulatory teams planning ANDA submissions or NDA filings for competing products need to assess claim scope before committing to formulation strategies.
PatSnap Eureka’s FTO Search Agent can map the claims of US11839689B2 against your product specifications, identify relevant prior art for invalidity analysis, and surface related Astellas patent families that may create additional clearance obligations. Use Eureka to build a landscape of enzalutamide and androgen receptor inhibitor patents, track prosecution history of application 17/985,235, and monitor the consolidated New Jersey litigation docket for dispositive rulings.
Run a freedom-to-operate analysis on US11839689B2 to assess your product’s exposure
Run FTO in Eureka →Similar ANDA patent cases involving oncology tablet formulations in NJ District Court
Cases involving branded oncology ANDA litigation in the District of New Jersey with multiple generic defendants and consolidation orders for prostate cancer therapies.
What this case signals for the pharmaceutical ANDA IP landscape
The rapid consolidation of parallel Xtandi® ANDA suits reflects a broader pattern in branded pharmaceutical enforcement strategy.
Multiple ANDA filers signal strong generic interest in enzalutamide
The existence of at least two parallel ANDA actions — Zydus Cadila and Haimen Pharma — filed within a short window suggests coordinated or near-simultaneous paragraph IV certifications. This pattern is consistent with high-value prostate cancer therapies attracting multiple first-filer candidates, increasing litigation complexity for the patent holder.
Consolidation strategy benefits Astellas in claim construction
By consolidating, Astellas secures a single claim construction ruling that binds all generic challengers. This prevents a scenario where one defendant obtains a favourable construction in a separate proceeding that another court could cite. For patent holders with multiple ANDA defendants, early stipulated consolidation is increasingly a preferred litigation posture.
Astellas v Zydus — key questions answered
The case was consolidated with Civil Action No. 3:24-cv-09403 after 98 days. Astellas filed suit on October 11, 2024, asserting US11839689B2 over Xtandi® tablets. No merits ruling was issued — all proceedings were merged into the lead docket by stipulation of all parties, including co-defendant Haimen Pharma, on January 17, 2025.
Astellas asserted US11839689B2 (application no. 17/985,235), covering formulations of Xtandi® (enzalutamide) tablets in 40 mg and 80 mg strengths. Enzalutamide is an androgen receptor inhibitor used in the treatment of prostate cancer. The patent was asserted in the context of Zydus Cadila’s ANDA filing targeting the Xtandi® product.
The consolidation was stipulated by all parties — Astellas, Zydus Cadila, and Haimen Pharma — to conserve judicial resources. Both actions involved the same patent (US11839689B2) and the same product (Xtandi® tablets), making consolidation the efficient procedural choice under FRCP 42(a). All future filings are directed to the lead docket 3:24-cv-09403.
No. Consolidation is a procedural mechanism that merges actions for efficiency — it does not dismiss or resolve any claims. Astellas’s infringement claims against Zydus Cadila under US11839689B2 remain active and will be litigated in the consolidated lead action, Civil Action No. 3:24-cv-09403, in the District of New Jersey.
Astellas was represented by Venable LLP and Walsh Pizzi O’Reilly Falanga LLP, with attorneys Christine Clark, Erin Austin, Katelyn O’Reilly, and Liza M. Walsh on record. Zydus Cadila was represented by Epstein Becker & Green PC, with Theodora T. McCormick as counsel of record.
PatSnap Eureka searches patents and litigation data to answer instantly.